Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIKALO-2: Tersolisib in advanced breast cancer
NCT07174336Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of tersolisib in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Overall Response Rate up to 5 years and Progression-Free Survival up to 5 years. Started Dec 2025; status: recruiting.
02
Drugs
tersolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07174336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174336.